ARDS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ARDS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Aridis Pharmaceuticals's Owner Earnings per Share (TTM) ended in Sep. 2023 was $0.00. It's Price-to-Owner-Earnings ratio for today is 0.
The historical rank and industry rank for Aridis Pharmaceuticals's Owner Earnings per Share (TTM) or its related term are showing as below:
Aridis Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Sep. 2023 was $-0.00. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.16. It's PE Ratio (TTM) ratio for today is At Loss.
Aridis Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2023 was $-0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.16. It's PE Ratio without NRI ratio for today is At Loss.
The historical data trend for Aridis Pharmaceuticals's Owner Earnings per Share (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aridis Pharmaceuticals Annual Data | ||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||
Owner Earnings per Share (TTM) | Get a 7-Day Free Trial | - | - | - | -2.08 | -1.44 |
Aridis Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Owner Earnings per Share (TTM) | Get a 7-Day Free Trial | -1.59 | -1.44 | -0.84 | -0.63 | -0.52 |
For the Biotechnology subindustry, Aridis Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Aridis Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Aridis Pharmaceuticals's Price-to-Owner-Earnings falls into.
In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
To make it simple, then you will have:
Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)
Aridis Pharmaceuticals's Owner Earnings per Share (TTM) Calculation:
TTM / Last Quarter | Average of Last 20 Quarters | |
Net Income | -1.14 | |
Depreciation, Depletion and Amortization | 0.31 | |
Change In Deferred Tax | 0.00 | |
5Y Average of Maintenance Capital Expenditure | 0.31 | |
Change In Working Capital | -18.45 | |
Shares Outstanding (Diluted Average) | 37.43 |
1. Start with "Net Income" from income statement. Aridis Pharmaceuticals's Net Income for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.14 Mil.
2. "Depreciation, Depletion and Amortization" is from cashflow statement. Aridis Pharmaceuticals's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Sep. 2023 was $0.31 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.
3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income.
Aridis Pharmaceuticals's Change In Deferred Tax for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.
4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $0.31 Mil
It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.
The following shows how to get maintenance capital expenditure.
First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.
Aridis Pharmaceuticals's 5-Year Average Maintenance Capital Expenditure = $0.31 Mil
5. "Change In Working Capital" is from cashflow statement. Aridis Pharmaceuticals's Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2023 was $-18.45 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.
6. Aridis Pharmaceuticals's Shares Outstanding (Diluted Average) for the months ended in Sep. 2023 was 37.429 Mil.
Aridis Pharmaceuticals's Onwer Earnings Per Share for Sep. 2023 is calculated as:
Owner Earnings per Share (TTM) | |||||
= | ( Net Income | + | Depreciation, Depletion and Amortization | + | Change In Deferred Tax |
= | ( -1.142 | + | 0.309 | + | 0 |
- | 5Y Avg of Maintenance CAPEX | + | Change In Working Capital ) | / | Shares Outstanding (Diluted Average) |
- | 0.30746666666667 | + | -18.454) | / | 37.429 |
= | 0.00 |
Price-to-Owner-Earnings | = | Current Price | / | Owner Earnings per Share (TTM) |
= | 0.0002 | / | 0.00 | |
= | 0 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.
Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.
Thank you for viewing the detailed overview of Aridis Pharmaceuticals's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.
Vu Truong | director, 10 percent owner, officer: CEO, CSO, Director | 5941 OPTICAL CT., SAN JOSE CA 95138 |
Eric Patzer | director, 10 percent owner | 5941 OPTICAL CT., SAN JOSE CA 95138 |
Fibrosis Foundation Cystic | 10 percent owner | 4550 MONTGOMERY STREET, SUITE 1100N, BETHESDA MD 20814 |
Hasan Jafri | officer: Chief Medical Officer | 5941 OPTICAL COURT, SAN JOSE CA 95138 |
John F Hamilton | director | 1360 O'BRIEN DR, MENLO PARK CA 94025 |
Michael Adrian Nazak | officer: Chief Financial Officer | 5941 OPTICAL COURT, SAN JOSE CA 95138 |
Susan Richards Windham-bannister | director | 78 BLANCHARD ROAD, BURLINGTON MA 01803 |
Isaac Blech | director | C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116 |
Fred Kurland | officer: Chief Financial Officer | C/O GENITOPE CORP, 525 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
Wolfgang Dummer | officer: Chief Medical Officer | 5491 OPTICAL CT., SAN JOSE CA 95138 |
Robert R Ruffolo | director | |
Shawn Lu | director | C/O CANTEX PHARMACEUTICALS, INC., 1792 BELL TOWER LANE, WESTON FL 33326 |
Robert K. Coughlin | director | 5941 OPTICAL CT., SAN JOSE CA 95138 |
Craig S Gibbs | director | C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025 |
From GuruFocus
By Value_Insider Value_Insider • 12-12-2022
By sperokesalga sperokesalga • 06-20-2023
By GuruFocus Research • 02-12-2024
By Marketwired • 06-24-2024
By Value_Insider Value_Insider • 11-22-2022
By sperokesalga sperokesalga • 03-31-2023
By Value_Insider Value_Insider • 11-22-2022
By sperokesalga sperokesalga • 05-31-2023
By Stock market mentor Stock market mentor • 01-25-2023
By Marketwired • 08-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.